Hair has always been more than just a style—especially in the Black community, where our coils, curls, and protective styles ...

Louis Theroux has released a new statement updating fans on his ongoing battle with alopecia. The BBC documentarian has been ...

Alopecia areata incidence was highest in patients in North America, Southeast Asia, and Australia, as well as in women and those aged 30 to 34 years.

Louis Theroux has revealed he is preparing for a "full head shave" due to his battle with alopecia.   The broadcaster, 54, ...

No new safety signals or reports of deaths, thromboembolic events, or major cardiovascular events reported. HealthDay News — For adults with severe alopecia areata (AA), ivarmacitinib, a selective ...

The rising prevalence of prediabetes among young adults signals early metabolic dysfunction, significantly increasing the risk of type 2 diabetes mellitus (T2DM) and associated complications.

Alopecia areata is an autoimmune disorder in which the immune system attacks hair follicles, leading to their inflammation and consequently to hair loss and impaired hair growth. The condition ...

For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 mg is efficacious and tolerable, according to a study presented at the ...

ORLANDO, FLA. — Janus kinase (JAK) inhibitors have revolutionized the treatment of alopecia areata (AA), and more drugs in this class are still in development for AA. However, a new therapy with ...

Long-term ritlecitinib was generally well tolerated among patients aged 12 years and older with alopecia areata and showed clinically meaningful efficacy through 3 years. Treatment with ritlecitinib ...

Please provide your email address to receive an email when new articles are posted on . Patients with severe to very severe alopecia areata saw hair regrowth with bempikibart treatment within 24 ...

Please provide your email address to receive an email when new articles are posted on . A phase 3 study compared two doses of ivarmacitinib with placebo in 330 adults. At week 24, about 35% in the ...